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Monash Institute of Reproduction and Develop-
ment (MIRD) and Prince Henry’s Institute of
Medical Research (PHIMR) are institutes with a
traditional focus on reproductive biology. Located
in Melbourne, they have expertise ranging from
male and female fertility/infertility, hormonal reg-
ulation, pre-implantation biology and screening,
sudden infant death syndrome, cancers of the repro-
ductive tract, early human development, assisted
reproductive technologies, endangered species con-
servation, and more recently, the development
and use of embryonic stem cells for strictly non-
reproductive purposes. This environment formed
the perfect setting for an international symposium
on reproductive genomics – a relatively new disci-
pline, which, judging from the high caliber of data
presented and the number of attendees, is being
embraced emphatically.
The meeting was opened by the Honourable John
Brumby (The Victorian State Government Treasurer
and Minister for State and Regional Development)
who signaled a bright future for Australian (and
Victorian in particular) biotechnology and its under-
pinning basic research, through a strong Govern-
ment ﬁnancial and legislative commitment to place
Victoria within the top ﬁve biotechnologies regions
world wide by 2010. The success of such a ven-
ture however, is solely dependent on attracting
and retaining the ‘best and brightest’ Australian
researchers through improved salary conditions and
support - a point that has long been heralded by
organizations such as The Australian Society for
Medical Research, but difﬁcult to meaningfully
implement in the face of biotechnology giants
based in the regions such as those around San
Diego, San Francisco Bay and Boston. This com-
mitment and the possibility of combining the very
attractive Australian lifestyle with improved work
conditions was, however, enthusiastically received.
The scientiﬁc sessions were started by Austin
Cooney (Baylor College of Medicine, TX) who
vividly highlighted the value of the mouse as a
model organism and the necessity for meticulous
phenotypic analyses in order to grasp the under-
lying biology. This theme was echoed by Margaret
Jones (PHIMR, Australia) and David Bowtell (Peter
MacCallum Cancer Institute, Australia) later in the
day. Austin presented his lab’s work on germ cell
nuclear factor (GCNF) and the various cre-lox
mouse models they have constructed to unravel its
importance in male and female reproductive bi-
ology. Male and female germ line speciﬁc gcnf dele-
tions were produced driven by sycp1 and zp3
promoter linked cre respectively. He showed that
despite the implementation of impressive molecular
biology and the success of ROSA assays, inactiva-
tion of the gcnf locus driven by sycp1 promoter
linked cre occurred in only 10% of male germ cells.
The zp3 driven excision was, however, very success-
ful, yet ovarian histology appeared normal and
females were fertile. Fortunately, through the
thorough (and at times no doubt heart breaking)
efforts of Austin’s post-docs, it was noticed that
the estrous cycle (and speciﬁcally diestrous) of
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Copyright # 2002 John Wiley & Sons, Ltd.knockout mice was approximately twice that of
control mice conﬁrming that, as suspected, gcnf is
indeed required for ‘normal’ ovarian function.
Margaret Jones presented a review of many years
of analysis on the aromatase knockout mouse (arko)
established by Evan Simpson’s laboratory and
the roles of aromatase, both obvious and subtle, in
female and male fertility. Further, Margaret pre-
sented new data on the success of arko mice
treated by intracytoplasmic sperm injection.
David Bowtell presented his laboratory’s work on
the sina/siah family of molecules in development
with an emphasis on the mechanism of meiotic
metaphase arrest and subsequent male infertility
seen in the siah1a knockout mouse.
Marilyn Monk’s (Institute of Child Health, UK,
and MIRD, Australia) research and presentation
revolved around the hypothesis that embryonic
genes are re-expressed in cancer cells i.e., both cell
types undergo genome wide demethylation, are
immortal, undifferentiated and invasive. Such pro-
teins/genes would represent ideal targets for the
treatment of cancer by DNA vaccines. In order to
explore this hypothesis the Monk group effectively
had to start from ‘scratch’ as existing expression
libraries and microarrays are derived from somatic
cells and, by deﬁnition, do not contain embryo-
speciﬁc sequences – and most certainly not of
human origin. In order to overcome obvious limita-
tions in obtaining tissue, cDNA libraries were
derived from single human oocytes and single
embryos from all of 2-cell, 4-cell and 8-cell stages,
blastocytes and primordial germ cells (PGCs) and
ampliﬁed. Embryo-speciﬁc sequences were obtained
using differential display by comparison to a panel
of 10-week fetal somatic tissues. Marilyn described
the preparation of these unique libraries and the
isolation of 3 previously unknown embryonic
sequences that are re-awakened in human tumors.
This investigation also highlighted the value of
research dollars spent on non-lethal conditions,
such as infertility, for perhaps more physically
taxing diseases such as cancer.
Gary Hime (University of Melbourne, Australia)
presented his work, and a literature review, on
Drosophila spermatogenesis and its value as a model
for mammalian systems. Speciﬁcally, there is a high
conservation of disease causing genes between ﬂies
and humans (y62%), they have short life cycles, are
easily genetically manipulated and are amenable
(from both a labour and dollar perspective) to
large, genome-wide analyses. Models outlined
included four-wheel drive (fwd), escargot and
several novel sequences obtained by the Hime
laboratory while looking for testicular stem cell
speciﬁc sequences.
Mary Stevens (Bayer Biotechnology, Berkeley,
CA) gave an introductory presentation on Bayer’s
research into viral delivery systems for their use in
the production of transgenic animals. Speciﬁcally
she spoke about their experiences with the adeno-
virus and adeno-associated virus (AAV) systems
and their use in models of asthma and cancer.
While not focusing on any reproductive disorders,
the asthma and cancer systems were seen as
forerunners for future research. By comparison to
the adenovirus system (ADEasy System), the AAV
system was found to produce longer term (perhaps
permanent), but lower level, more physiological
over-expression, but was limited by a relatively
small insert size of y4.5 kb, difﬁcult construction
and unregulated production of largely soluble pro-
teins. Both systems appeared to have advantages
over more traditional methods of transgenic
mouse production for addressing speciﬁc biological
questions.
The potential value of viral delivery systems is
beginning to be realized in the clinic, as outlined in
the presentation by Leland Chung (Emory Univer-
sity, GA). Leland presented his group’s results on
the use of adenovirus-based vectors in combination
with more traditional therapies such as anti-
angiogenic drugs, antibody and growth factor
conjugated toxins and radiation therapy for the
treatment of prostate cancer. These investigations
demonstrated that targeted gene therapy was able
to limit metastasis, however Leland also cautioned
that to be more effective, improvements in viral
targeting need to be made.
The application of microarrays to the study of
reproductive disorders has been whole-heartedly
and productively embraced by reproductive biol-
ogists. These techniques provide a detailed picture
of complex genetic diseases and have emerged as an
important research tool, which is being extended
into clinical diagnosis. Steve Smith (Cambridge
University, UK) presented his work on human
female infertility and outlined the signiﬁcant medi-
cal problems, and the lack of data, surrounding the
time of pre-implantation. The lack of data is caused
by the difﬁculties in obtaining human tissues and
the increased complexity of human implantation
compared to mice, and as such, the paucity of
suitable model systems. Steve’s lab has used the
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human genome) and subsequently tailored mem-
brane-based arrays to assess differences between
individual patient samples of proliferative and
secretory endometrium in order to understand the
origin of various types of menstrual/angiogenesis
based conditions. Using this method, 11 marker
genes were identiﬁed. He noted that the variation
between patients was often greater than the differ-
ences between disease states when looking at an
individual gene level. As such, it is imperative for
researchers to look at cassettes of gene expression,
including the level of expression, in order to get a
grasp on the underlying biology. A systems biology
approach to the understanding of disease through
the use of microarray expression proﬁles may
require complex analyses and the recruitment of
traditionally mathematical minds.
Nabeel Affara (Cambridge University, UK) has
very successfully used glass slide based arrays of
largely testis-speciﬁc sequences. They have used
four gene sets: 1. Testis-speciﬁc sequence libraries
from all of human, mice and pig, produced by
subtraction of testis RNA with RNA from somatic
tissues (1300, 5400, and 4700 clones respectively); 2.
Mouse testis RNA subtracted with Sxr
b mouse
testis RNA (which lack germ cells) (2000 clones); 3.
the McCarrey/Eddy gene set of germ cell transcripts
(y8000 clones) and 4. the National Institute of
Ageing (NIA) mouse embryo gene set (y15 000
clones or y50% of the mouse transcriptome). These
arrays have been used to assess expression differ-
ences between various RNA samples including
those derived from human somatic tissues, testicu-
lar cell lines (GC1, GC2, TM3 and TM4) and
mouse testes of deﬁned ages to identify truly testis-
speciﬁc sequences, and those speciﬁcally involved in
the ﬁrst wave of spermatogenesis. Reference probes
for all were derived from either adult mouse or
human testis RNA. Importantly, all analyses were
done using both combinations of ﬂuorochromes
i.e., test and reference cDNAs labeled with both
ﬂuorochromes. Only those showing a signiﬁcant
fold increase/decrease with both labels were taken
as meaningful.
Peter Koopman (Institute of Molecular Bioscience,
Australia) presented his laboratory’s work on the
use of microarrays for the discovery of genes (and
transcriptional differences) involved in either testis
or ovary development. Membrane arrayed samples
consisted of male versus female (and vice versa)
subtracted and normalized libraries generated using
suppression PCR; the NMUR library (Greenﬁeld/
Soares) and unselected cDNA sets derived from
NIA and RIKEN sequences. Genes involved in
female or male sex determination were identiﬁed
from critical stages of embryogenesis (i.e., 11 days
or 13 days), by analysis of differentially expressed
RNA on DNA microarrays. Sequences were ana-
lyzed using various bioinformatics programs and
results validated, and the expressing cells deter-
mined, using whole-mount in situ hybridization.
Results were presented for vanin-1 and several
novel sequences. Vanin-1 was shown to be localized
at the surface of Sertoli cells and be involved in
testis development and cord formation through the
use of the urogenital ridge co-culture assay.
Vince Harley (PHIMR, Melbourne) addressed the
accumulating knowledge of genes critical in the
determination of ‘maleness’, a theme that was
rather amusingly expanded upon from an evolu-
tionary perspective by Jenny Graves (The Australian
National University, Australia). Through genomic
approaches, such as those presented by Peter
Koopman, and more traditional molecular biologi-
cal/transgenic approaches, the ﬁeld is moving
rapidly towards an understanding of the critical
events in sex determination. The Y chromosome
may not be the sex determining ‘powerhouse’ it was
once purported to be, but rather an ‘whimpish’
remnant of chromosomal history slated for destruc-
tion.
As a further dimension to the ﬁeld of sex
determination, Eric Vilain (University of California
Los Angeles, CA) presented his work on dosage-
sensitive sex reversal, and speciﬁcally WNT-4.
Further, he presented some of the consequences of
the misguided, although well meaning, intentions of
surgeons operating on inter-sex human patients, a
point that vividly highlighted the necessity for
increased communication between medical re-
searchers, medical staff and patients.
The proteomics session began with Jenny Harry
(Proteome Systems, Australia), who outlined their
strategy for high throughput 2D gel analysis and
presented some of their results on body ﬂuid and
tissue derived biomarkers of ovarian cancer. Treat-
ment of ovarian cancer is critically dependent upon
early diagnosis (>90% survival rate), but is rarely
diagnosed until it has reached late stage (>85% of
cases). Jenny also outlined the development of their
ProteoChip (membrane immobilized spots) which
will allow for sample storage and subsequent re-
analysis.
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presented their work on a surface enhanced laser
desorption and ionization (SELDI) platform and
the success of this machine in searching for disease
progression markers including those for ovarian
carcinomas and prostate cancer.
Peter Hudson (CSIRO, Australia) provided an
overview of the emerging ﬁeld of protein arrays and
their potential applications in the discovery of
biomarkers, and in the development of protein
chips as point of care diagnostic devices. Techni-
ques for the development of stable protein chips are
still being developed, however, by coupling antigens
or dimers and trimers of recombinant antibody
fragments to hydrated surfaces, the promise of
protein chips as a complement to DNA microarrays
is becoming a reality.
Chris Goodnow (The Australian National Univer-
sity, Australia) gave an elegant illustration of the
strategy for, and value of, large-scale ENU muta-
genesis programs by effectively dissecting the T cell
differentiation pathway using mice with names such
as ‘Buffy’, ‘Willow’ and ‘Xander’. A theme that was
expanded upon by Chris Ormandy (Garvan Institute,
Australia) who has used ENU mutagenized mice
from Chris Goodnow’s colony to identify genes
involved in mammary gland development and carci-
nogenesis. After an initial screen using mutagenized
C57BL/6 mice, the Ormandy lab has subsequently
moved onto using sensitized mouse lines such as those
carrying the SV40 T antigen or sensitizing transgenes
(e.g., myc and wnt) in order to recover a greater
percentage of cancer promoting mutations.
If there was any doubt as to the value of the
mouse as a model system, its genetic potential was
hammered home by Simon Foote (The Walter and
Eliza Hall Institute, Australia) who has used mouse
strain differences to map genetic modiﬁers of
disease. Speciﬁcally, his laboratory has used strain
susceptibility differences to Leishmania major or
tumorigenesis to map quantitative trait loci (QTL).
Once identiﬁed, candidate regions were validated by
the production of BAC transgenic mice to assess
disease resistance on an otherwise susceptible back-
ground. Importantly, all regions mapped by the
laboratory have been QTLs. They have never
isolated a Mendelian single gene trait, thus
underscoring the value of large linkage based
analyses, where possible, over the candidate gene
approach.
The value of the translation of high quality
animal model research into a human setting was
emphasized by the work presented by Ken McEl-
reavey (Pasteur Institute, France) on Y chromosome
deletions and haplogroups in spermatogenic failure,
high sperm counts and twinning. Further, the value
of the observant clinical eye and memory was left in
no doubt. Most excitingly, Ken presented the
discovery (in collaboration with Prof. Golubovsky,
St Petersburg, Russia) of families with a Y chromo-
some linked predisposition to twinning (and mis-
carriage). Until now, the origin of all twinning was
believed to be either multiple ovulation or zygote/
early embryo cleavage. Amazingly these families
were spread across four countries, shared the same
surname (and indeed Y chromosome) and could be
traced back to a common ancestor in 17
th Century
Scotland. Currently the mechanism by which this
happens is unknown.
Other highlights of the meeting included the
presentations by Paul Hertzog (MIRD, Australia)
on chromosome 21 genes and diseases. His group
has successfully constructed several chromosome 21
gene mouse models, which have shed light not only
upon Down Syndrome pathology, but also on the
etiology of more widespread conditions including
viral susceptibility (ifnar1 and infar2 knockout
mice), neuronal degeneration (ets2 knockout) and
kidney degeneration (adamts-1 knockout). Carina
Dennis (Nature Publishing Group, Washington DC)
discussed the considerable problems associated with
archiving and disseminating the massive amounts of
data generated by genomic-based programs and
presented some potential solutions. Andrew Elefanty
(Walter and Eliza Hall Institute and MIRD,
Australia) and Martin Pera (MIRD, Australia)
presented a front-line view of embryonic stem cell
research and its ultimate potential for human
therapies. A session that was nicely followed up
by Bob Williamson (Murdoch Children’s Research
Institute, Australia), who presented a potential road
map through the mineﬁeld of ethics associated with
stem cell technologies and a look back at the path
taken for reproductive technologies.
Finally the meeting was concluded with a
presentation by John Mattick (Institute of Molecu-
lar Biosciences, Australia) who gave his perspectives
on the value of the human genome and some
potential answers to the lower than expected gene
number found for humans. His fascinating ideas
and data on non-coding RNAs and their role in all
levels of gene, mRNA and protein regulation left
the audience with no doubt that genome research
has a long and glorious path ahead of it.
208 Meeting Review
Copyright # 2002 John Wiley & Sons, Ltd. Comp Funct Genom 2002; 3: 205–208.